In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists

European Journal of Clinical Investigation

Volumn 37, Issue 9, 2007, Pages 700-708

  Bocci, G ^a   Culler, M D ^b   Fioravanti, A ^a   Orlandi, P ^a   Fasciani, A ^a,c   Colucci, R ^a   Taylor, J E ^b   Sadat, D ^b   Danesi, R ^a   Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Biomeasure Inc   (United States)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

Human angiogenesis; Somatostatin analogs; Somatostatin subtype 1 receptor

Indexed keywords

BIM 23745; BIM 23926; FIBRIN; HORMONE RECEPTOR STIMULATING AGENT; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1 AGONIST; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SELECTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MICROVASCULATURE; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANGIOGENESIS INHIBITORS; GENE EXPRESSION; HUMANS; RECEPTORS, SOMATOSTATIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN;

EID: 34547894232     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01848.x     Document Type: Article

References (38)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 1 : 27 31.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42.
3. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003 2 : 999 1017.
4. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004 1014 : 121 31.
5. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991 12 : 450 82.
6. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002 57 : 425 41.
7. Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 2000 278 : H1815 22.
8. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 2005 92 : 1493 8.
9. Yan S, Li M, Chai H, Yang H, Lin PH, Yao Q et al. TNF-alpha decreases expression of somatostatin, somatostatin receptors, and cortistatin in human coronary endothelial cells. J Surg Res 2005 123 : 294 301.
10. Cervera P, Videau C, Viollet C, Petrucci C, Lacombe J, Winsky-Sommerer R et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol 2002 14 : 458 71.
11. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991 50 : 245 51.
12. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996 45 : 49 50.
13. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997 3 : 265 72.
14. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001 92 : 545 50.
15. Kumar M, Liu ZR, Thapa L, Chang Q, Wang DY, Qin RY. Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol 2004 10 : 393 9.
16. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. Faseb J 1999 13 : 647 55.
17. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003 144 : 1574 84.
18. Grant MB, Caballero S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) 2002 38 : 783 91.
19. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 1992 18 : 438 44.
20. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001 86 : 140 5.
21. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M et al. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002 297 : 828 34.
22. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997 99 : 789 98.
23. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992 99 : 683 90.
24. Bocci G, Danesi R, Fioravanti A, Del Tacca M. The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells. Pharmacol Res 2002 45 : 21 5.
25. Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol 2004 498 : 9 18.
26. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin- C-induced apoptosis. Cancer Chemother Pharmacol 2000 45 : 389 96.
27. Eden PA, Taylor JE. Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci 1993 53 : 85 90.
28. Bocci G, Danesi R, Del Tacca M, Kerbel RS. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. Eur J Pharmacol 2003 477 : 17 21.
29. Bocci G, Fasciani A, Danesi R, Viacava P, Genazzani AR, Del Tacca M. In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. Mol Hum Reprod 2001 7 : 771 7.
30. Yang H, Nan B, Yan S, Li M, Yao Q, Chen C. C-reactive protein decreases expression of VEGF receptors and neuropilins and inhibits VEGF165-induced cell proliferation in human endothelial cells. Biochem Biophys Res Commun 2005 333 : 1003 10.
31. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995 55 : 376 85.
32. Buchan AM, Lin CY, Choi J, Barber DL. Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration. J Biol Chem 2002 277 : 28431 8.
33. Hukovic N, Rocheville M, Kumar U, Sasi R, Khare S, Patel YC. Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. J Biol Chem 1999 274 : 24550 8.
34. Florio T, Thellung S, Arena S, Corsaro A, Bajetto A, Schettini G et al. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol Paris 2000 94 : 239 50.
35. Adams RL, Adams IP, Lindow SW, Atkin SL. Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin Endocrinol (Oxf) 2004 61 : 431 6.
36. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005 438 : 967 74.
37. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996 137 : 4046 9.
38. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 2001 86 : 2161 9.